Apoptosis and Chemoresistance in Human Ovarian Cancer: Is Xiap a Determinant?

NeuroSignals

Volumn 9, Issue 2, 2000, Pages 122-130

  Li, Julang ^a   Sasaki, Hiromasa ^a   Sheng, Ying Lun ^a   Schneiderman, Danielle ^a   Xiao, Chao Wu ^a   Kotsuji, Fumikazu ^b   Tsang, Benjamin K ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

Apoptosis; Caspases; Chemoresistance; Fas Fas ligand; Focal adhesion kinase; Gene therapy; Human ovarian cancer; Inhibitor of apoptosis proteins; MDM2; p53

Indexed keywords

CASPASE; CISPLATIN; DNA; FAS ANTIGEN; FAS LIGAND; FOCAL ADHESION KINASE; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN MDM2; PROTEIN P53; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; XIAP;

APOPTOSIS; CANCER RESISTANCE; GENE THERAPY; HUMAN; OVARY CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEINS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 0034104017     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000014631     Document Type: Article

References (47)

1. Sherman SE, Lippard SJ: Structural aspects of platinum anticancer drug interaction with DNA. Chem Rev 1987;87:1153-1157.
2. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG: Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994;54:3500-3505.
3. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997;137:231-245.
4. Fichtinger-Schepmen AMJ, van der Veer JL, den Hartog JHJ, Lohman PHM, Reedijk J: Adducts of the antitumor drug cis-diamminedichloro-platinum (II) with DNA: Formation, identification and quantitation. Biochemistry 1985;24:707-713.
5. Eastman A: Reevaluation of interaction of cis-dechloro(ethylenediam-ine) platinum (II) with DNA. Biochemistry 1986;25:3912-3915.
6. Crul M, Schellens JHM, Beijnen JH, Maliepaard M: Cisplatin resistance and DNA repair. Cancer Treatment Reviews 1997;23:341-366.
7. 2 phase and cell and cell death induced by cispla-tin. J Natl Cancer Inst 1990;82:749-755.
8. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death by cisplatin, other anti-cancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-2362.
9. Itoh N, Yonehara S, Ishii A, Yone-hara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoding the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66: 233-243.
10. Suda T, Nagata S: Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994;179:873-879.
11. Kim JM, Boone DL, Auyeung A, Tsang BK: Granulosa cell apoptosis induced at the penultimate stage of follicular development is associated with increased levels of Fas and Fas ligand in the rat ovary. Biol Reprod 1998;58:1170-1176.
12. Wakahara Y, Nawa A, Okamoto T, Hayakawa A, Kikkawa F, Suganama N, Wakahara F, Tomoda Y: Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncology 1997;54:48-54.
13. Uslu R, Jewett A, Bonavida B: Sen-sitzation of human ovarian tumor cells by subtoxic CDDP to anti-Fas antibody-mediated cytotoxicity and apoptosis. Gynecol Oncol 1996;62: 282-291.
14. Muller M, Strand S, Hug H, Heine-mann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403-413.
15. Schneiderman D, Kim JM, Senter-man M, Tsang BK: Sustained suppression of Fas ligand expression in cisplatin-resistant human surface epithelial cancer cells. Apoptosis 1999;4:1-11
16. Birnbaum MJ, Clem RJ, Miller LK: An apoptosis inhibiting gene from a nuclear polyhedrosis virus encoding a peptide with Cys/His sequence motifs. J Virol 1994;68: 2521-2528.
17. Crook NE, Clem RJ, Miller LK: An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993;67:2168-2174.
18. Roy N, Mahadevan MS, Mclean M, Shutler G, Yaraghi Z, Farahni R, Baird S, Besner-Johnston A, Lefebvre C, Kang X, Salih M, Aubry H, Tamai K, Guan X, Ioannou P, Crawford TO, Jong PJD, Korneluk RG, MacKenzie A: The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995;80:167-178.
19. Liston P, Roy N Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Fara-hani R, McLean M, Ikeda J-E, MacKenzie A, Korneluk RG: Suppression of apoptosis in mammalian cells by Naip and a related family. Nature 1996;379:349-353.
20. Uren AG, Pakusch M Hawkins C.J, Puls KL, Vaux DL: Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci USA 1996;93: 4974-4978.
21. Duckett CS, Nava, VE, Gedrich RW, Clem RJ, Van Dongen JL, Gil-filan MC, Sheils H, Hardwick JM, Thompson CB: A conserved family of cellular genes related to the bacu-lovirus iap gene and encoding apoptosis inhibitors. EMBO J 1996; 15: 2685-2694.
22. Rothe M, Pan M-G, Henzel WJ, Ayres TM, Goeddel DV: The TNFR2-TRAF signalling complex contains two novel proteins related to baculovirus inhibitor of apoptosis proteins. Cell 1995;83:1243-1252.
23. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, surviv-in, expressed in cancer and lymphoma. Nature Med 1997;3:917-921.
24. Chandler JM, Cohen G.M, MacFar-lane M: Different subcellular distribution of caspase-3 and caspase-7 following Fas-induced apoptosis in mouse liver. J Biol Chem 1998; 273: 10815-10818.
25. Takemura Y, Kobayashi H, Miya-chi H, Hayashi K, Sekiguchi S, Oh-numa T: The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro. Cancer Chemother Pharmacol 1991;27:417-422.
26. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, surviv-in, expressed in cancer and lymphoma. Nature Med 1997;3:917-921.
27. Deveraux QL, Takahashi R, Salve-sen G.S, Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-304.
28. Li J, Feng Q, Kim J-M, Schneider-man D, Liston P, Li M, Vander-hyden B, Faught W, Fung MFK, Korneluk RG, Senterman M, Tsang BK: Ovarian cancer and cisplatin resistance: Roles of inhibitor of apoptosis proteins, unpubl.
29. Kerr JF, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994;73:2013-2026.
30. Schlaepfer DD, Hunter T: Integrin signalling and tyrosine phosphorylation: Just the FAKs? Trends Cell Biol 1998; 8:151-157.
31. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J: Matrix adhesion and Ras transformation both activate a phos-phoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997; 16:2783-2793.
32. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY: Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996;134: 793-799.
33. Hungerford JE, Compton MT, Matter ML, Hoffstrom BG, Otey CA: Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. J Cell Biol 1996;135:1383-1390.
34. Ilic D, Furuta Y, Kanazawa S, Take-da N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-defi-cient mice. Nature 1995;377:539-544.
35. Crouch DH, Fincham VJ, Frame MC: Targeted proteolysis of the focal adhesion kinase pp125 FAK during c-MYC-induced apoptosis is suppressed by integrin signalling. Oncogene 1996;12:2689-2696.
36. Thornberry NA, Lazebnik Y: Cas-pases: Enemies within. Science 1998;281:1312-1316.
37. Lazebnik YA, Kaufmann SH, Des-noyers S, Poirier GG, Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346-347.
38. Widmann C, Gibson S, Johnson GL: Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apop-totic signals. J Biol Chem 1998; 273: 7141-7147.
39. Sakahira H, Enari M, Nagata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391: 96-99.
40. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997;16:6914-6925.
41. Sasaki H, Kotusji F Tsang BK: Cis-platin-induced, caspase-3-mediated focal adhesion kinase processing in human ovarian cancer cells: Possible regulation by X-linked inhibitor of apoptosis protein, unpubl.
42. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
43. Barak Y, Juven T, Haffner R, Oren M: MDM2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-468.
44. Chen L, Agrawal S, Zhou W, Zhang R, Chen J: Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci US 1998;95: 195-200.
45. Erhardt P, Tomaselli KJ, Cooper GM: Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J Biol Chem 1997;272:15049-15052.
46. Chen L, Marechal V, Moreau J, Levine AJ, Chen J: Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J Biol Chem 1997;272: 22966-22973.
47. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7: 1126-1132.